Bethesda, Maryland 20892


Purpose:

Cystic fibrosis is a disease that affects many parts of the body, particularly the lungs and pancreas. The main purpose of this study is to further understand the natural history, clinical presentation, and genetics of cystic fibrosis. Patients with cystic fibrosis will be asked to participate in this study by undergoing standard medical tests and procedures. Patients will have a history taken and have a physical examination as well as blood tests, and a sweat test (a test for cystic fibrosis of the pancreas in which electrolytes are measured in collected sweat). Patients may also be asked to provide samples of urine, stool, and sputum for additional tests. More complicated procedures such as bronchoscopy or bronchoalveolar lavage may be required for diagnosis, treatment, or research purposes. Patients will receive appropriate treatment with antibiotics, pancreatic enzymes, vitamins, physiotherapy, and other agents. Medications may be given by mouth or injected into a vein. This study will provide patients with information on the prognosis of the disease as well as recommendations for management of cystic fibrosis. In addition this study will provide information to researchers which may be useful in other studies of cystic fibrosis.


Study summary:

This is an omnibus protocol for studying patients with cystic fibrosis and other familial pulmonary and pancreatic disorders. The main purpose of the study is to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis. A well-characterized population of patients with cystic fibrosis will be invited to provide appropriate specimens for laboratory research and to participate in clinical trials of therapeutic agents for cystic fibrosis.


Criteria:

- INCLUSION CRITERIA Patients and family members with known or suspected CF and related disorders of the respiratory tract or pancreas as defined by clinical presentation, sweat testing and/or genotyping. Willingness of patients, or guardian to give informed consent. EXCLUSION CRITERIA Age less than 4 years. Concomitant medical, psychiatric or other problems which might complicate interpretation of studies of CF, or for which we are unable to provide adequate care.


NCT ID:

NCT00001223


Primary Contact:

Principal Investigator
Milica S Chernick, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Milica S Chernick, M.D.
Phone: (301) 496-3434
Email: milicac@bdg10.niddk.nih.gov


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20892
United States

For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)
Phone: 800-411-1222
Email: prpl@mail.cc.nih.gov

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.